Interestingly, they inhibit the expression of OCT4/SOX2 or CD133 in human GBM cell line by targeting specifically their promoters, as well as decrease tumor growth both in vitro and in vivo, but fail to eradicate completely the tumor [54]. Here, SOX2 is linked to neoplasm.